Q-omics provides the consensus-scored GCSIR profile across patient tissues and cancer cell-line models. GCSIR expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, GCSIR is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, GCSIR RNA expression shows 9,101 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, COAD, and THYM as cancer lineages where GCSIR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GCSIR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GCSIR survival associations across molecular data types. GCSIR RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GCSIR RNA expression–survival associations across cancer types. High GCSIR expression shows unfavorable associations in STAD, LGG, DLBC, KICH, KIRC and ESCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for GCSIR RNA expression.
This table summarizes GCSIR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GCSIR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GCSIR shows lower tumor expression in COAD, KICH and READ and higher tumor expression in LUAD. The COAD box plot shows higher GCSIR RNA expression in normal versus tumor tissue (log2 FC = −0.191, t-test p < 0.001).
This table shows molecular features associated with GCSIR in patient tissues and cancer cell lines. In patient samples, GCSIR shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
